NVS — Expiration of Patent US8846650 for CIPRODEX
Jun 4, 2025, 12:00:00 AM UTC
Summary
The patent for CIPRODEX (US8846650) is set to expire on June 4, 2025. CIPRODEX, an antibiotic ear drop solution, is used to treat ear infections, particularly those caused by bacteria. Its patent expiration may open the market to generic alternatives, potentially leading to reduced prices and increased competition. This could significantly impact revenue for the product's current holder and provide cost-saving options for patients and healthcare providers.
Company
NOVARTIS AG (NVS)NYSE — Healthcare: Manufacturing, Drug Manufacturers - General: Pharmaceutical Preparations
www.novartis.comSimilar Events
Expiration of Patent US9549929 for CIBINQO
Patent US9549929 for CIBINQO, a Jak inhibitor developed by Pfizer, is set to expire on February 19, 2034. The patent covers pyrrolo{2,3-d}pyrimidine derivatives utilized in the formulation of this treatment. The expiration of this patent may allow for increased competition in the market, potentially impacting Pfizer's revenue from CIBINQO as generic versions could enter the market shortly after expiration.
Patent ExpirationExpiration of Patent US8148374 for PREZCOBIX
The patent US8148374 related to PREZCOBIX, a HIV-1 treatment, assigned to Gilead Sciences Inc and JANSSEN PRODUCTS LP, will expire on September 3, 2029. This patent protects the formulation and therapeutic methods associated with the compound, which is crucial for maintaining exclusivity in the market. With expiration, generic competition may increase, potentially impacting revenue for both companies.
Patent ExpirationExpiration of Patent US9884039 for FUROSCIX
The patent US9884039 for FUROSCIX, a liquid formulation of furosemide developed by ScPharmaceuticals Inc., is set to expire on April 3, 2034. The patent relates to a novel formulation that enhances the stability of furosemide for subcutaneous delivery. As patent expiration approaches, ScPharmaceuticals could face increased competition in the market as generics may become available, potentially impacting its revenue from this product.
Patent ExpirationExpiration of Patent US11097061 for DEXYCU KIT
Patent US11097061 for the DEXYCU KIT, developed by Icon Bioscience Inc and EyePoint Pharmaceuticals Inc, is set to expire on June 23, 2039. DEXYCU is a kit designed to facilitate the precise loading and delivery of small volume doses of medication, particularly at treatment sites, such as the conclusion of ocular surgeries. The expiration of this patent could potentially lead to increased competition in the market, as generics may emerge, impacting the financial landscape for the companies involved.
Patent